Company / Capital Expenditures
Immix Biopharma, Inc. Capital Expenditures History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$1.2M
FY2025
5-year range
$52.1K / $1.2M
FY2023-FY2025
Trend
+2160.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures changed +2161% YoY in FY2025, a notable deviation from the 2-year average annual change of +1080%.
Based on SEC 10-K filings.
$1M in FY2025.
Improved from $52,089 to $1M over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, capital expenditures increased 2160.9% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.83 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.2M | +2160.9% |
| FY2024 | $52.1K | +0.0% |
| FY2023 | $52.1K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026